On April 27, 2021 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "company") reported, with approval of the Supervisory Board, to increase the company’s share capital through a rights issue using the Authorized Capital 2020/II (Press release, Epigenomics, APR 27, 2021, View Source [SID1234578594]). The share capital shall be increased from currently EUR 9,852,690.00 by up to EUR 1,970,538.00 to up to EUR 11,823,228.00 by issuing up to 1,970,538 new registered no par value shares of the company against cash contributions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The subscription price of the new shares was set at EUR 1.10. The new shares will be offered to the company’s shareholders as part of a public offering in Germany by way of indirect subscription rights during the subscription period, which is expected to run from 3 May 2021 to 17 May 2021. The subscription ratio will be 5:1. This means that for each 5 existing shares of the company, a subscription right for 1 new share is allocated. The company will strive to place new shares that are not subscribed during the subscription period with selected investors. M.M.Warburg & CO (AG & Co.) Kommanditgesellschaft auf Aktien is accompanying the transaction.